natgillin/translations-raw huggingface dataset:
The CLARITY trial included 3,491 patients presenting within 12 hours of the onset of a ST elevation MI and planned for thrombolytic therapy.
Studija CLARITY uključivala je 3491 bolesnika, koji su unutar posljednjih 12 sati doživjeli infarkt miokarda s elevacijom ST-segmenta i planirana im je trombolitička terapija.
• Hypersensitivity to the active substances or to any of the excipients listed in section 2 or section
• Preosjetljivosti na djelatne tvari ili bilo koju od pomoćnih tvari lijeka navedenih u dijelu 2. ili dijelu 6.1.
After a single oral dose of 75 mg, clopidogrel has a half-life of approximately 6 hours.
Nakon jednokratne peroralne doze od 75 mg poluvrijeme izlučivanja klopidogrela iznosi otprilike 6 sati.
10 film-coated tablets 14 film-coated tablets 28 film-coated tablets 30 film-coated tablets 50 film-coated tablets 90 film-coated tablets 100 film-coated tablets
10 filmom obloženih tableta 14 filmom obloženih tableta 28 filmom obloženih tableta 30 filmom obloženih tableta 50 filmom obloženih tableta 90 filmom obloženih tableta 100 filmom obloženih tableta
Low doses (up to 100 mg/day):
Niske doze (do 100 mg/dan):
• sudden life-threatening allergic reactions
• iznenadne, po život opasne alergijske reakcije
• The active substances are clopidogrel and acetylsalicylic acid.
• Djelatne tvari su klopidogrel i acetilsalicilatna kiselina.
Salicylic acid in the combination of clopidogrel/acetylsalicylic acid has a plasma half-life of approximately 2 hours.
Poluvijek salicilatne kiseline iz kombinacije klopidogrel/acetilsalicilatna kiselina u plazmi iznosi približno 2 sata.
Repeated doses of clopidogrel 75 mg per day produced substantial inhibition of ADP-induced platelet aggregation from the first day; this increased progressively and reached steady state between Day 3 and Day 7.
Ponovljene doze klopidogrela od 75 mg na dan uzrokuju snažnu inhibiciju ADP-om posredovane agregacije trombocita od prvoga dana; to se progresivno pojačava i dostiže stanje dinamičke ravnoteže između 3. i 7. dana.
Patients with pre-existing mastocytosis, in whom the use of acetylsalicylic acid may induce severe hypersensitivity reactions (including circulatory shock with flushing, hypotension, tachycardia and vomiting).
Bolesnici s već postojećom mastocitozom, u kojih primjena acetilsalicilatne kiseline može uzrokovati teške reakcije preosjetljivosti (uključujući cirkulatorni šok uz navale crvenila, hipotenziju, tahikaridiju i povraćanje).
• In patients with gout since low doses of ASA increase urate concentrations.
• U bolesnika s gihtom jer manje doze ASK povećavaju koncentracije urata.
Due to the presence of both components of the medicinal product, Clopidogrel/Acetylsalicylic acid Teva is contraindicated in case of:
Zbog prisustva obje tvari u lijeku, lijek Klopidogrel/acetilsalicilatna kiselina Teva kontraindiciran je u slučaju:
A crossover study in 40 healthy subjects, 10 each in the four CYP2C19 metaboliser groups (ultrarapid, extensive, intermediate and poor), evaluated pharmacokinetic and antiplatelet responses using 300 mg followed by 75 mg/day and 600 mg followed by 150 mg/day, each for a total of 5 days (steady state).
U ukriženoj studiji na 40 zdravih ispitanika, po 10 iz svake od 4 skupine CYP2C19 metabolizatora (vrlo brzi, brzi, intermedijarni i spori), procijenjen je farmakokinetički i antitrombocitni odgovor upotrebom doze od 300 mg, nakon čega je slijedila doza od 75 mg/dan te doze od 600 mg, nakon čega je slijedila doza od 150 mg/dan, u trajanju od ukupno 5 dana (stanje dinamičke ravnoteže).
If the use of the combination of clopidogrel/acetylsalicylic acid is discontinued, patients may benefit with continuation of one antiplatelet medicinal product.
Ako se prekine primjena kombinacije klopidogrela i acetilsalicilatne kiseline, bolesniku može koristiti nastavak liječenja pojedinačnim antitrombotskim lijekom.
No clinical data on exposure to the combination of clopidogrel/acetylsalicylic acid during pregnancy are available.
Nisu dostupni klinički podaci o izloženosti kombinaciji klopidogrel/acetilsalicilatna kiselina tijekom trudnoće.
• probenecid, benzbromarone, or sulfinpyrazone, medicines used to treat gout,
• probenecid, benzbromaron ili sulfinpirazon, lijekove koji se koriste za liječenje gihta
• oral anticoagulants, medicines used to reduce blood clotting,
• oralne antikoagulanse, lijekove koji sprječavaju zgrušavanje krvi
Taste disturbances
poremećaj okusa
• In patients with a history of asthma or allergic disorders since they are at increased risk of hypersensitivity reactions
• U bolesnika koji u anamnezi imaju astmu ili alergijske poremećaje, jer imaju povećan rizik od razvoja reakcija preosjetljivosti
More than 30,000 patients entered into clinical trials with clopidogrel plus ASA at maintenance doses lower than or equal to 325 mg, and received a variety of concomitant medicinal products including diuretics, beta blockers, ACE Inhibitors, calcium antagonists, cholesterol lowering agents, coronary vasodilators, antidiabetic agents (including insulin), antiepileptic agents and GPIIb/IIIa antagonists without evidence of clinically significant adverse interactions.
Više od 30 000 bolesnika sudjelovalo je u kliničkim ispitivanjima u kojima su uz klopidogrel i ASK u dozama održavanja od 325 mg ili manjima, istovremeno primali niz različitih lijekova, među kojima su bili diuretici, beta blokatori, ACE inhibitori, antagonisti kalcija, lijekovi za snižavanje kolesterola, koronarni vazodilatatori, antidijabetici (uključujući inzulin), antiepileptici te antagonisti glikoproteina IIb/IIIa, bez dokaza klinički značajnih štetnih interakcija.
If you become pregnant while taking Clopidogrel/Acetylsalicylic acid Teva, consult your doctor immediately as it is recommended not to take Clopidogrel/Acetylsalicylic acid Teva while you are pregnant.
Ako zatrudnite za vrijeme uzimanja lijeka Klopidogrel/acetilsalicilatna kiselina Teva, odmah se posavjetujte s liječnikom jer nije preporučeno uzimati Klopidogrel/acetilsalicilatna kiselina Teva za vrijeme trudnoće.
Due to the presence of ASA, the combination of clopidogrel/acetylsalicylic acid is contraindicated during the third trimester of pregnancy.
Zbog ASK u svom sastavu, kombinacija klopidogrel/acetilsalicilatna kiselina kontraindicirana je tijekom trećeg tromjesečja trudnoće.
107c(7) of Directive 2001/83/EC and published on the European medicines web-portal.
Nositelj odobrenja će periodička izvješća o neškodljivosti za ovaj lijek podnositi u skladu s referentnim popisom datuma EU (EURD popis) predviđenim člankom 107(c) stavkom 7 Direktive 2001/83/EZ i objavljenim na europskom internetskom portalu za lijekove.
This benefit was consistent across age, gender and with or without fibrinolytics, and was observed as early as 24 hours.
Ta korist je bila dosljedna bez obzira na dob, spol i primjenu fibrinolitika, a opažena je već unutar 24 sata od početka liječenja.
Patients should be evaluated for history of hypersensitivity to another thienopyridine (such as clopidogrel, ticlopidine, prasugrel) since cross-reactivity among thienopyridines has been reported (see section 4.8).
Potrebno je provjeriti imaju li bolesnici u povijesti bolesti zabilježenu preosjetljivost na neki drugi tienopiridin (primjerice klopidogrel, tiklopidin, prasugrel) jer je prijavljena križna reaktivnost među tienopiridinima (vidjeti dio 4.8).
As a dual antiplatelet agent, the combination of clopidogrel/acetylsalicylic acid should be used with caution in patients who may be at risk of increased bleeding from trauma, surgery or other pathological conditions and in patients receiving treatment with other NSAIDs including Cox-2 inhibitors, heparin, glycoprotein IIb/IIIa inhibitors, selective serotonin reuptake inhibitors (SSRIs), or thrombolytics.
Kao dvostruki antitrombotski lijek, kombinaciju klopidogrela i acetilsalicilatne kiseline potrebno je s oprezom davati bolesnicima koji mogu biti izloženi riziku od pojačanog krvarenja zbog traume, kirurških zahvata ili drugih patoloških stanja te bolesnicima koji se liječe drugim nesteroidnim protuupalnim lijekovima (NSAIL), uključujući Cox-2 inhibitore, heparin, inhibitore glikoproteina Ilb/IIIa, selektivne inhibitore ponovne pohrane serotonina ili trombolitike.
Clopidogrel/Acetylsalicylic acid Teva contains lactose If you have been told by your doctor that you have an intolerance to some sugars (e.g. lactose), contact your doctor before taking this medicine.
Klopidogrel/acetilsalicilatna kiselinaTeva sadrži laktozu Ako Vam je liječnik rekao da ne podnosite neke šećere (npr. laktozu), obratite mu se prije nego što počnete uzimati ovaj lijek.
• ASA or another non-steroidal anti-inflammatory medicine usually used to treat painful and/or inflammatory conditions of muscle or joints,
• ASK ili druge nesteroidne protuupalne lijekove koji se obično koriste za liječenje bolnih i/ili upalnih stanja mišića ili zglobova
Based on the pharmacokinetic and metabolic characteristics of both compounds, clinically significant PK interactions are unlikely
S obzirom na farmakokinetička i metabolička svojstva obje djelatne tvari, nije vjerojatna pojava klinički značajnih farmakokinetičkih interakcija.
Acetylsalicylic acid inhibits platelet aggregation by irreversible inhibition of prostaglandin cyclo-oxygenase and thus inhibits the generation of thromboxane A2, an inducer of platelet aggregation and vasoconstriction.
Acetilsalicilatna kiselina inhibira agregaciju trombocita ireverzibilnom inhibicijom prostaglandin ciklo-oksigenaze i time inhibira stvaranje tromboksana A2, induktora agregacije trombocita i vazokonstrikcije.
In addition, IPA was 32% (24 hours) and 61% (Day 5), which were greater than in the poor metabolisers receiving the 300 mg/75 mg regimen, and were similar to the other CYP2C19 metaboliser groups receiving the 300 mg/75 mg regimen.
Dodatno, vrijednost IPA iznosila je 32% (24 sata) i 61% ( 5. dan), što je više nego u sporih metabolizatora koji su primali režim doziranja od 300 mg/75 mg i bila je slična ostalim skupinama CYP2C19 metabolizatora koje su primale režim od 300 mg/75 mg.
Breast-feeding should be discontinued during treatment with the combination of clopidogrel/acetylsalicylic acid.
Dojenje je potrebno prekinuti tijekom liječenja kombinacijom klopidogrel/acetilsalicilatna kiselina.
What Clopidogrel/Acetylsalicylic acid Teva is and what it is used for What you need to know before you take Clopidogrel/Acetylsalicylic acid Teva How to take Clopidogrel/Acetylsalicylic acid Teva
Što je Klopidogrel/acetilsalicilatna kiselina Teva i za što se koristi Što morate znati prije nego počnete uzimati Klopidogrel/acetilsalicilatna kiselina Teva Kako uzimati Klopidogrel/acetilsalicilatna kiselina Teva Moguće nuspojave
• Non-ST segment elevation acute coronary syndrome (unstable angina or non-Q-wave myocardial infarction) including patients undergoing a stent placement following percutaneous
• akutnog koronarnog sindroma bez elevacije ST-segmenta (nestabilna angina ili non-Q infarkt miokarda), uključujući bolesnike koji se podvrgavaju ugradnji stenta nakon perkutane koronarne intervencije
If any of the situations mentioned below apply to you, you should tell your doctor before taking Clopidogrel/Acetylsalicylic acid Teva:
Ako se na Vas odnosi bilo koje od dolje navedenih stanja, morate obavijestiti liječnika prije nego što uzmete Klopidogrel/acetilsalicilatna kiselina Teva:
• carbamazepine, or oxcarbazepine, medicines to treat some forms of epilepsy,
• karbamazepin ili okskarbazepin, lijekove koji se koriste u liječenju nekih oblika epilepsije
After first opening the bottle use within 30 days.
Nakon prvog otvaranja boce, lijek potrošiti u roku od 30 dana.
Patients received clopidogrel (75 mg/day, n=22,961) plus ASA (162 mg/day), or ASA alone (162 mg/day) (n=22,891), for 28 days or until hospital discharge.
Bolesnici su primali klopidogrel (75 mg dnevno, N=22 961) uz ASK (162 mg dnevno) ili samo ASK (162 mg dnevno, N=22 891) tijekom 28 dana ili do otpusta iz bolnice.
Pack size of 30 film-coated tablets.
Pakiranja sa 30 filmom obloženih tableta.
Esomeprazole is expected to give a similar interaction with clopidogrel.
Očekuju se slične interakcije između esomeprazola i klopidogrela.
Bleeding is the most common reaction reported both in clinical studies as well as in the post-marketing experience where it was mostly reported during the first month of treatment.
Najčešće prijavljivana nuspojava u kliničkim ispitivanjima i u praćenju nakon stavljanja lijeka u promet je krvarenje, a zabilježeno je najčešće tijekom prvog mjeseca liječenja.
• swelling in the mouth
• oticanje u ustima
Pack sizes of 14, 28 and 30 film-coated tablets.
Pakiranja sa 14, 28 i 30 filmom obloženih tableta.
The 2x2 factorial design COMMIT trial included 45,852 patients presenting within 24 hours of the onset of the symptoms of suspected MI with supporting ECG abnormalities (i.e. ST elevation, ST depression or left bundle-branch block).
COMMIT, studija faktorskog dizajna 2x2, uključivala je 45 852 bolesnika sa simptomima suspektnog infarkta miokarda u zadnja 24 sata i pratećim abnormalnostima EKG-a (primjerice ST elevacija, ST depresija ili blok lijeve grane).
How to store Clopidogrel/Acetylsalicylic acid Teva Contents of the pack and other information
Kako čuvati Klopidogrel/acetilsalicilatna kiselina Teva Sadržaj pakiranja i druge informacije
• inflammation of small vessels.
• upala malih krvnih žila.
The combination of clopidogrel/acetylsalicylic acid should be used with caution in patients who receive concomitant glycoprotein IIb/IIIa inhibitors (see section 4.4).
Kombinaciju klopidogrela i acetilsalicilatne kiseline potrebno je s oprezom davati bolesnicima koji istodobno primaju inhibitore glikoproteina IIb/IIIa (vidjeti dio 4.4.).
Depending on your condition, your doctor will determine the length of time for which you need to take Clopidogrel/Acetylsalicylic acid Teva.
Ovisno o Vašem stanju, liječnik će odrediti duljinu liječenja lijekom Klopidogrel/acetilsalicilatna kiselina Teva.
Pharmacogenetics: In patients who are poor CYP2C19 metabolisers, clopidogrel at recommended doses forms less of the active metabolite of clopidogrel and has a smaller effect on platelet function.
Farmakogenetika: u bolesnika koji su spori CYP2C19 metabolizatori, pri primjeni preporučenih doza klopidogrela stvara se manja količina aktivnog metabolita lijeka te je smanjen učinak na funkciju trombocita.
• fluconazole, voriconazole, ciprofloxacin, or chloramphenicol, medicines to treat bacterial and fungal infections,
• flukonazol, vorikonazol, ciprofloksacin ili kloramfenikol, lijekove koji se koriste za liječenje bakterijskih i gljivičnih infekcija
After the 300 mg/75 mg dose regimen, antiplatelet responses were decreased in the poor metabolisers with mean IPA (5 μM ADP) of 24% (24 hours) and 37% (Day 5) as compared to IPA of 39% (24 hours) and 58% (Day 5) in the extensive metabolisers and 37% (24 hours) and 60% (Day 5) in the intermediate metabolisers.
Nakon režima doziranja od 300 mg/75 mg, antitrombocitni odgovor bio je smanjen u sporih metabolizatora sa srednjom vrijednosti IPA (5 μM ADP) od 24% (nakon 24 sata) te 37% (5. dan), u usporedbi s vrijednostima IPA-e od 39% (24 sata) i 58% (5. dan) za brze metabolizatore te 37% (24 sata) i 60% (5. dan) za intermedijarne metabolizatore.
In particular, in a post-hoc analysis in 2,172 patients (17% of the total CURE population) who underwent stent placement (Stent-CURE), the data showed that clopidogrel compared to placebo, demonstrated a significant RRR of 26.2% favouring clopidogrel for the co-primary endpoint (CV death, MI, stroke) and also a significant RRR of 23.9% for the second co-primary endpoint (CV death, MI, stroke or refractory ischaemia).
U post-hoc analizi 2172 bolesnika (17% ukupne CURE populacije) koji su se podvrgli ugradnji stenta (Stent-CURE), podaci su pokazali da je klopidogrel u usporedbi s placebom, pokazao značajno smanjenje relativnog rizika od 26,2% za koprimarni ishod (smrt zbog kardiovaskularnih uzroka, infarkt miokarda, moždani udar) kao i značajno smanjenje relativnog rizika od 23,9% za drugi koprimarni ishod (smrt zbog kardiovaskularnih uzroka, infarkt miokarda, moždani udar ili refraktorna ishemija).
Due to the presence of ASA, methotrexate used at doses higher than 20 mg/week should be used with caution with the combination of clopidogrel/acetylsalicylic acid as it can inhibit renal clearance of methotrexate, which may lead to bone marrow toxicity.
Metotreksat primjenjivan u dozama višima od 20 mg/tjedan potrebno je koristiti s oprezom s kombinacijom klopidogrel/acetilsalicilatna kiselina jer zbog ASK u sastavu, ta kombinacija može inhibirati bubrežni klirens metotreksata, što može dovesti do toksičnosti za koštanu srž.
• ticlopidine, other antiplatelet agent.
• tiklodipin, druge antitrombotičke lijekove.
Renal excretion of unchanged active substance depends upon urinary pH. As urinary pH rises above 6.5, the renal clearance of free salicylate increases from <5% to >80%.
Kad se pH urina poveća iznad 6,5, bubrežni klirens slobodne frakcije salicilata poveća se sa <5% na >80%.
Interactions with the following medicinal products with higher (anti-inflammatory) doses of ASA have also been reported: angiotensin converting enzyme (ACE) inhibitors, acetazolamide, anticonvulsants (phenytoin and valproic acid), beta blockers, diuretics, and oral hypoglycemic agents.
Zabilježene su i interakcije sljedećih lijekova s višim (protuupalnim) dozama ASK: inhibitori angiotenzin konvertirajućeg enzima (ACE inhibitori), acetazolamid, antikonvulzivi (fenitoin i valproatna kiselina), beta blokatori, diuretici i oralni hipoglikemici.
What you need to know before you take Clopidogrel/Acetylsalicylic acid Teva
Što morate znati prije nego počnete uzimati Klopidogrel/acetilsalicilatna kiselina Teva
Since clopidogrel is metabolised to its active metabolite partly by CYP2C19, use of medicinal products that inhibit the activity of this enzyme would be expected to result in reduced drug levels of the active metabolite of clopidogrel.
Budući da se klopidogrel do svog aktivnog metabolita djelomično metabolizira enzimom CYP2C19, očekuje se da će primjena lijekova koji inhibiraju aktivnost tog enzima dovesti do pada razine aktivnog metabolita klopidogrela.
Fifteen percent (15.0%) of patients in the clopidogrel plus ASA group and 21.7% in the group treated with ASA alone reached the primary endpoint, representing an absolute reduction of 6.7% and a 36% odds reduction in favor of clopidogrel (95% CI: 24, 47%; p <0.001), mainly related to a reduction in occluded infarct-related arteries.
Primarni ishod dostiglo je 15,0% bolesnika u skupini s klopidogrelom uz ASK te 21,7% u skupini samo s ASK, što predstavlja apsolutno smanjenje od 6,7% i smanjenje šansi od 36% u korist klopidogrela (95% CI: 24, 47%; p<0,001), uglavnom povezano sa smanjenjem okluzija u koronarnim arterijama povezanih s infarktom.
Clopidogrel/Acetylsalicylic acid Teva contains lactose.
Klopidogrel/acetilsalicilatna kiselina Teva sadrži laktozu.
• You should also tell your doctor immediately if you develop a medical condition (also known as Thrombotic Thrombocytopenic Purpura or TTP) that includes fever and bruising under the skin that may appear as red pinpoint dots, with or without unexplained extreme tiredness, confusion, yellowing of the skin or eyes (jaundice) (see section 4 ‘Possible side effects').
• Odmah obavijestite svog liječnika ako se pojavi bolest (poznata kao trombotička trombocitopenična purpura ili TTP) sa simptomima koji uključuju vrućicu i potkožne hematome koji se mogu pojaviti kao crvene točkice, s neobjašnjivim izrazitim umorom, zbunjenošću i žutom bojom kože ili očiju (žutica) ili bez njih (vidjeti dio 4. „Moguće nuspojave“).
Rare side effect (may affect up to 1 in 1000 people): • vertigo.
Rijetke nuspojave (mogu se javiti u do 1 na 1000 osoba): • vrtoglavica.
• sensation of tingling and numbness.
• osjećaj trnaca i utrnulost
Mean peak plasma levels of unchanged clopidogrel (approximately 2.2-2.5 ng/ml after a single 75 mg oral dose) occurred approximately 45 minutes after dosing.
Srednja vrijednost vršnih koncentracija nepromijenjenog klopidogrela u plazmi (oko 2,2-2,5 ng/ml nakon jednokratne peroralne doze od 75 mg), postiže se otprilike 45 minuta nakon uzimanja lijeka.
In CURE there was no excess in major bleeds with clopidogrel plus ASA within 7 days after coronary bypass graft surgery in patients who stopped therapy more than five days prior to surgery.
U studiji CURE, u kojoj je klopidogrel primjenjivan uz ASK, nije bilo povećanja broja velikih krvarenja tijekom 7 dana nakon ugrađivanja srčane premosnice u bolesnika koji su lijekove prestali uzimati više od pet dana prije kirurškog zahvata.
Consistent with the above results, in a meta analysis including 6 studies of 335 clopidogrel-treated subjects at steady state, it was shown that active metabolite exposure was decreased by 28% for intermediate metabolisers, and 72% for poor metabolisers while platelet aggregation inhibition (5 μM ADP) was decreased with differences in IPA of 5.9% and 21.4%, respectively, when compared to extensive metabolisers.
U skladu s gore navedenim rezultatima, u meta analizi koja je uključivala 6 studija sa 335 osoba liječenih klopidogrelom u stanju dinamičke ravnoteže, pokazano je da je izloženost aktivnom metabolitu smanjena za 28% za intermedijarne metabolizatore te 72% za spore metabolizatore, dok je inhibicija agregacije trombocita (5 µM ADP) smanjena s razlikama za vrijednosti IPA-e od 5,9%, odnosno 21,4%, u usporedbi sa brzim metabolizatorima.
After repeated doses of 75 mg clopidogrel per day in subjects with severe renal disease (creatinine clearance from 5 to 15 ml/min), inhibition of ADP-induced platelet aggregation was lower (25%) than that observed in healthy subjects, however, the prolongation of bleeding time was similar to that seen in healthy subjects receiving 75 mg of clopidogrel per day.
Nakon ponovljenih doza od 75 mg klopidogrela dnevno, inhibicija ADP-om inducirane agregacije trombocita bila je niža (25%) u ispitanika s teškim oštećenjem funkcije bubrega (klirens kreatinina od 5 do 15 ml/min), u usporedbi sa zdravim ispitanicima, iako je produljenje vremena krvarenja bilo slično onom zabilježenom u zdravih ispitanika koji su primali 75 mg klopidogrela dnevno.
Following absorption, the ASA in the combination of clopidogrel/acetylsalicylic acid is hydrolyzed to salicylic acid with peak plasma levels of salicylic acid occurring within 1 hour of dosing, such that plasma levels of ASA are essentially undetectable 1.5-3 hours after dosing.
Nakon apsorpcije, ASK iz kombinacije klopidogrel/acetilsalicilatna kiselina se hidrolizira u salicilatnu kiselinu čija se vršna koncentracija u plazmi pojavljuje unutar jednog sata od primjene, tako da je koncentraciju ASK u plazmi gotovo nemoguće odrediti poslije 1,5-3 sata nakon doziranja.
This benefit was consistent across all prespecified subgroups including patients' age and gender, infarct location, and type of fibrinolytic or heparin used.
Ova korist bila je dosljedno prisutna u svim unaprijed određenim podskupinama prema dobi i spolu bolesnika, lokaciji infarkta te tipu primijenjenog fibrinolitika ili heparina.
Other concomitant therapy with ASA
Ostala istodobna terapija s ASK
What Clopidogrel/Acetylsalicylic acid Teva is and what it is used for
Što je Klopidogrel/Acetilsalicilatna kiselina Teva i za što se koristi
It is unknown whether ASA alters fertility.
Nije poznato utječe li ASK na plodnost.
Clopidogrel/Acetylsalicylic acid Teva is used following initiation of therapy with clopidogrel and ASA given separately.
Klopidogrel/acetilsalicilatna kiselina Teva koristi se nakon početka liječenja u kojem se klopidogrel i ASK daju odvojeno.
If you have any further questions on the use of this medicine, ask your doctor or pharmacist.
U slučaju bilo kakvih pitanja u vezi s primjenom ovoga lijeka obratite se svom liječniku ili ljekarniku.
• ST segment elevation acute myocardial infarction in medically treated patients eligible for
• akutnog infarkta miokarda s elevacijom ST segmenta u medikamentozno liječenih bolesnika podobnih za liječenje tromboliticima
Clopidogrel/Acetylsalicylic acid Teva is a fixed-dose combination medicinal product for continuation of therapy in:
Klopidogrel/acetilsalicilatna kiselina Teva je fiksna kombinacija lijeka za nastavak liječenja: